SCHEMBL5545905

SCHEMBL5545905

CCCCN1CC(C)(C)c2cc(C)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
LMNA P02545 3/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
POLB P06746 1/20 0.39
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TP53 P04637 1/20 0.35
KMT2A Q03164 5/20 0.34
MEN1 O00255 4/20 0.34
HTT P42858 4/20 0.34
KDM4E B2RXH2 3/20 0.34
PGR P06401 1/20 0.33
RORA P35398 1/20 0.33
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542487 0.95 RARB (0.43) ALDH1A1LMNATSHRMAPTSMN1; SMN2
SCHEMBL5544189 0.94 RARB (0.45) ALDH1A1LMNATSHRMAPTSMN1; SMN2
SCHEMBL5540500 0.91 ALDH1A1 (0.40) ALDH1A1LMNATSHRMAPTSMN1; SMN2
SCHEMBL5542437 0.84 ALDH1A1 (0.39) ALDH1A1LMNATSHRMAPTSMN1; SMN2
SCHEMBL5545900 0.84 RARB (0.38) ALDH1A1LMNATSHRRARBRARG
SCHEMBL10331081 0.80 NOTUM (0.49)
SCHEMBL5542480 0.79 RARB (0.42) ALDH1A1LMNATSHRRARBRARG
SCHEMBL5544184 0.78 RARB (0.44) ALDH1A1RARBRARG
SCHEMBL22346077 0.77 KMT2A (0.42) ALDH1A1LMNATSHRMAPTSMN1; SMN2
SCHEMBL5536032 0.75 ALDH1A1 (0.43) ALDH1A1LMNATSHRMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885LMNA 4152/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.